Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

NCT00380887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2006-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.

Conditions

  • Postmenopause

Interventions

DRUG

Premarin

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380887 on ClinicalTrials.gov